$TLSA News

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

Tiziana Completes Phase 2a MS Trial, Topline Data Due In October

Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026